يعرض 1 - 7 نتائج من 7 نتيجة بحث عن '"Iacoboni G."', وقت الاستعلام: 0.91s تنقيح النتائج
  1. 1
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Rejeski K Department of Medicine III – Hematology/Oncology, University Hospital, LMU Munich, Munich, Germany. Laboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany. German Cancer Consortium (DKTK), Munich and Berlin Sites, and German Cancer Research Center, Heidelberg, Germany. Adult BMT and Cellular Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY. Wang Y, Bansal R Division of Hematology, Mayo Clinic, Rochester, MN. Hansen DK Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL. Iacoboni G, Barba P Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Bachy E Department of Hematology, Lyon Sud Hospital, INSERM 1052, Pierre-Bénite, France, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: Blood Advances;8(8); https://doi.org/10.1182/bloodadvances.2023011767Test; Rejeski K, Wang Y, Hansen DK, Iacoboni G, Bachy E, Bansal R, et al. Applying the EHA/EBMT Grading for ICAHT after CAR-T: Comparative Incidence and Association with Infections and Mortality. Blood Adv. 2024 Apr 23;8(8):1857–1868.; https://hdl.handle.net/11351/11330Test

  2. 2
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Chatzikonstantinou T, Minga E, Chamou D Institute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece. Scarfò L Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy. Karakatsoulis G Institute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece. Department of Mathematics, University of Ioannina, Ioannina, Greece. Iacoboni G Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: eClinicalMedicine;65; https://doi.org/10.1016/j.eclinm.2023.102307Test; Chatzikonstantinou T, Scarfò L, Karakatsoulis G, Minga E, Chamou D, Iacoboni G, et al. Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY. eClinicalMedicine. 2023 Nov;65:102307.; https://hdl.handle.net/11351/10847Test

  3. 3
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Bücklein V Department of Medicine III, University Hospital, LMU Munich, Germany. Laboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany. Perez A Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL, USA. Blood and Marrow Transplant Program, Miami Cancer Institute, Miami, FL, USA. Rejeski K Department of Medicine III, University Hospital, LMU Munich, Germany. Laboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany. German Cancer Consortium (DKTK) Munich Site, and German Cancer Research Center (DKFZ), Heidelberg, Germany. Iacoboni G Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Jurinovic V Institute for Medical Information Processing, Biometry, and Epidemiology, LMU Munich, Germany. Holtick U Department I of Internal Medicine, Medical Faculty and University Hospital, Cologne, University of Cologne, Germany, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: HemaSphere;7(8); https://doi.org/10.1097/HS9.0000000000000907Test; Bücklein V, Perez A, Rejeski K, Iacoboni G, Jurinovic V, Holtick U, et al. Inferior Outcomes of EU Versus US Patients Treated With CD19 CAR-T for Relapsed/Refractory Large B-cell Lymphoma: Association With Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR-T Product Use. HemaSphere. 2023 Jul 11;7(8):e907.; https://hdl.handle.net/11351/10105Test; 001029914500001

  4. 4
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Abrisqueta P, Iacoboni G, Serna A, Cabirta A, Bosch F Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Nadeu F Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain. Department of Pathology, Hospital Universitari de Bellvitge-Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain. Bosch-Schips J Department of Pathology, Hospital Universitari de Bellvitge-Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: Cancer Treatment Reviews;120; https://doi.org/10.1016/j.ctrv.2023.102619Test; info:eu-repo/grantAgreement/ES/PE2013-2016/PI18%2F01392; Abrisqueta P, Nadeu F, Bosch-Schips J, Iacoboni G, Serna A, Cabirta A, et al. From genetics to therapy: Unraveling the complexities of Richter transformation in chronic lymphocytic leukemia. Cancer Treat Rev. 2023 Nov;120:102619.; https://hdl.handle.net/11351/10286Test

  5. 5
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Abrisqueta P, Tazón-Vega B, Iacoboni G, Bobillo S, Marín-Niebla A, Bosch F Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Medina D, Carabia J, Boix J, Crespo M Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Villacampa G Oncology Data Science (OdysSey) Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Lu J European Molecular Biology Laboratory (EMBL), Heidelberg, Germany. Alcoceba M, González M Department of Hematology, University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Center for Cancer Research-IBMCC (USAL-CSIC), Salamanca, Spain. Zenz T Department of Medical Oncology and Hematology, University Hospital and University of Zurich, Zurich, Switzerland, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: Blood Advances;6(21); https://doi.org/10.1182/bloodadvances.2022007508Test; info:eu-repo/grantAgreement/ES/PE2013-2016/PI17%2F00950; info:eu-repo/grantAgreement/ES/PE2013-2016/PI17%2F00943; info:eu-repo/grantAgreement/ES/PE2013-2016/PI18%2F01392; Abrisqueta P, Medina D, Villacampa G, Lu J, Alcoceba M, Carabia J, et al. A gene expression assay based on chronic lymphocytic leukemia activation in the microenvironment to predict progression. Blood Adv. 2022 Nov 8;6(21):5763–73.; https://hdl.handle.net/11351/8701Test

  6. 6
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Jiménez I, Nieto JC, Carabia J, Munuera M, Puigdefàbregas L, Crespo M Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Tazón-Vega B, Abrisqueta P, Bobillo S, Palacio-García C, Iacoboni G, Bosch F Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Franco-Jarava C Servei d’Immunologia, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: Biomarker Research;9; https://doi.org/10.1186/s40364-021-00290-zTest; info:eu-repo/grantAgreement/ES/PE2013-2016/PI17%2F00950; info:eu-repo/grantAgreement/ES/PE2013-2016/PI18%2F01392; info:eu-repo/grantAgreement/ES/PE2013-2016/PI17%2F00943; Jiménez I, Tazón-Vega B, Abrisqueta P, Nieto JC, Bobillo S, Palacio-García C, et al. Immunological and genetic kinetics from diagnosis to clinical progression in chronic lymphocytic leukemia. Biomark Res. 2021 May 20;9:37.; https://hdl.handle.net/11351/6800Test; 000652611500001

  7. 7
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Hutchings M Department of Hematology and Phase 1 Unit, Rigshospitalet, Copenhagen, Denmark. Morschhauser F Université de Lille, CHU Lille, ULR 7365 - GRITA - Groupe de Recherche sur les formes Injectables et les Technologies Associées, Lille, France. Iacoboni G Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Carlo-Stella C Humanitas Clinical and Research Center—IRCCS and Humanitas University, Rozzano, Italy. Offner FC Ghent University, Ghent, Belgium. Sureda A Institut Català d’Oncologia-Hospitalet, Institut d’Investigació Biomèdica de Bellvitge, Universitat de Barcelona, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: Journal of Clinical Oncology;39(18); http://dx.doi.org/10.1200/JCO.20.03175Test; Hutchings M, Morschhauser F, Iacoboni G, Carlo-Stella C, Offner FC, Sureda A, et al. Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell–Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial. J Clin Oncol. 2021 Jun 20;39(18):1959–70.; https://hdl.handle.net/11351/7761Test; 000628819400029